This is an erratum to: Wolfgang Dichtl and others, Low rates of inappropriate shocks in contemporary real-world implantable cardioverter defibrillator patients: the CARAT observational study, EP Europace, Volume 25, Issue 9, September 2023, euad186, https://doi.org/10.1093/europace/euad186
In the originally published version of this manuscript, there was an error in the following sentence, whereby the term ‘adenosine triphosphate’ was erroneously included in the sentence during the production process:
‘A VT zone was enabled from 170 bpm on average, with adenosine triphosphate 1 (ATP1) burst/adenosine triphosphate 2 (ATP2) ramp and shocks in the vast majority of patients.’
As defined in the paper, ‘ATP’ stands for ‘AntiTachycardia Pacing’, and so this sentence has been corrected to read as follows:
‘A VT zone was enabled from 170 bpm on average, with AntiTachycardia Pacing 1 (ATP1) burst/AntiTachycardia Pacing 2 (ATP2) ramp and shocks in the vast majority of patients.'
In addition, in Table 1, the percentage given for “Primary prevention of SCD” was originally given as 75.3% and this has been corrected to 77.0%.